Nucala for hypereosinophilic syndrome – pro
Nucala is a monoclonal antibody that works by reducing levels of eosinophils (a type of white blood cell). High eosinophil levels can contribute to certain disorders. Nucala is used together with other medicines to help control severe asthma in adults and children who are at least 6 years old. NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for >=6 months without an identifiable non-hematologic secondary cause.
The indication does not require use of another medication concurrently.
Marc E. Rohenberg et, Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. N Engl J Med 2008; 358:1215-1228
Alves Júnior JM, Prota FE, Villagelin D, Bley F, Bernardo WM. Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis. Clinics (Sao Paulo). 2021 Oct 11;76:e3271.
Nucala Prescribing Information 2024